相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes
Ramasamy Thilagavathi et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2022)
Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyteATPhomeostasis during substrate challenge
Brian E. Ford et al.
DIABETES OBESITY & METABOLISM (2020)
Ex Vivo Method to Simultaneously Evaluate Glucose Utilization, Uptake, and Production in Rat Liver
Yoshinori Tsumura et al.
ANALYTICAL SCIENCES (2019)
TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
Aoife Egan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Hussein Al Jobori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models
Yoshinori Tsumura et al.
PLOS ONE (2017)
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes
Ziad H. Al-Oanzi et al.
DIABETES OBESITY & METABOLISM (2017)
Glucokinase activation is beneficial or toxic to cultured rat pancreatic islets depending on the prevailing glucose concentration
Leticia P. Roma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Type 2 Diabetes and Congenital Hyperinsulinism Cause DNA Double-Strand Breaks and p53 Activity in β Cells
Sharona Tornovsky-Babeay et al.
CELL METABOLISM (2014)
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
A. Kiyosue et al.
DIABETES OBESITY & METABOLISM (2013)
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
Jun-ichi Eiki et al.
MOLECULAR PHARMACOLOGY (2011)
Assessing the potential of glucokinase activators in diabetes therapy
Franz M. Matschinsky
NATURE REVIEWS DRUG DISCOVERY (2009)
Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression
UJ Desai et al.
DIABETES (2001)
分享论文
